An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable (HCC) (CA209-956)
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 17 Jul 2019 Status changed from active, no longer recruiting to recruiting.
- 24 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2019 Results of the interim analysis (n=17) presented at the 55th Annual Meeting of the American Society of Clinical Oncology